GAITHERSBURG, Md. (WJZ) — Novavax introduced Thursday its vaccine candidate proved to be 96.4% efficient in opposition to gentle, reasonable and extreme instances of COVID-19 in a Section 3 trial in the UK.
The Gaithersburg-based biotech firm additionally introduced the entire evaluation of its Section 2b trial happening in South Africa, with efficacy of 55.4% among the many HIV- unfavourable trial contributors in a area the place the overwhelming majority of strains are B1.351 escape variants.
Throughout each trials, NVX-CoV2373 demonstrated 100% safety in opposition to extreme illness, together with all hospitalization and dying, Novavax stated.
— Novavax (@Novavax) March 11, 2021
Stanley Erck, President and CEO of Novavax, issued the next assertion in a information launch:
“We’re very inspired by the info displaying that NVX-CoV2373 not solely supplied full safety in opposition to essentially the most extreme types of illness, but in addition dramatically decreased gentle and reasonable illness throughout each trials. Importantly, each research confirmed efficacy in opposition to the variant strains. At present marks one yr for the reason that WHO formally declared the COVID-19 pandemic, and with this information in hand, we’re much more motivated to advance our vaccine as a possible weapon within the combat to finish the struggling brought on by COVID-19.”
In each the U.Okay. and South Africa trials, these analyses confirmed that the vaccine is well-tolerated, with low ranges of extreme, critical (SAEs) and medically attended antagonistic occasions at day 35, balanced between vaccine and placebo teams, Novavax added.